Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials

被引:9
作者
Athauda, Avani [1 ]
Nankivell, Matthew [2 ]
Langer, Rupert [3 ]
Pritchard, Susan [4 ]
Langley, Ruth E. [2 ]
von Loga, Katharina [1 ]
Starling, Naureen [1 ]
Chau, Ian [1 ]
Cunningham, David [1 ]
Grabsch, Heike I. [5 ,6 ]
机构
[1] Royal Marsden NHS Fdn Trust, Dept Gastrointestinal Oncol & Lymphoma, London, England
[2] UCL, Clin Trials Unit, MRC, London, England
[3] Kepler Univ Klinikum, Klin Inst Pathol & Mol Pathol, Linz, Austria
[4] Manchester Univ NHS Fdn Trust, Wythenshawe Hosp, Dept Pathol, Manchester, England
[5] Maastricht Univ, GROW Sch Oncol & Reprod, Dept Pathol, Med Ctr, Maastricht, Netherlands
[6] Univ Leeds, Leeds Inst Med Res, Div Pathol & Data Analyt, St Jamess Univ, Leeds, England
关键词
PERIOPERATIVE CHEMOTHERAPY; OPEN-LABEL; NEOADJUVANT; ESOPHAGEAL; MULTICENTER; GRADE;
D O I
10.1038/s41416-023-02217-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundNo definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival.MethodsData and samples from two large prospective randomised trials (UK MRC OE05 and ST03) were pooled. Stained slides were available for central pathology review from 1619 patients. Mandard tumour regression grade (TRG) and regression of tumour within LNs (LNR: scored as present/absent) were assessed and correlated with overall survival (OS) using a Cox regression model. An exploratory analysis to define subgroups with distinct prognoses was conducted using a classification and regression tree (CART) analysis.ResultsNeither trial demonstrated a relationship between TRG score and the presence or absence of LNR. In univariable analysis, lower TRG, lower ypN stage, lower ypT stage, presence of LNR, presence of well/moderate tumour differentiation, and absence of tumour at resection margin were all associated with better OS. However, the multivariable analysis demonstrated that only ypN, ypT, grade of differentiation and resection margin (R0) were independent indicators of prognosis. Exploratory CART analysis identified six subgroups with 3-year OS ranging from 83% to 22%; with ypN stage being the most important single prognostic variable.ConclusionsPathological LN stage within the resection specimen was the single most important determiner of survival. Our results suggest that the assessment of regression changes within the primary tumour or LNs may not be necessary to define the prognosis further.
引用
收藏
页码:2036 / 2043
页数:8
相关论文
共 30 条
[1]   Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].
Al-Batran, Salah-Eddin ;
Homann, Nils ;
Pauligk, Claudia ;
Goetze, Thorsten O. ;
Meiler, Johannes ;
Kasper, Stefan ;
Kopp, Hans-Georg ;
Mayer, Frank ;
Haag, Georg Martin ;
Luley, Kim ;
Lindig, Udo ;
Schmiegel, Wolff ;
Pohl, Michael ;
Stoehlmacher, Jan ;
Folprecht, Gunnar ;
Probst, Stephan ;
Prasnikar, Nicole ;
Fischbach, Wolfgang ;
Mahlberg, Rolf ;
Trojan, Joerg ;
Koenigsmann, Michael ;
Martens, Uwe M. ;
Thuss-Patience, Peter ;
Egger, Matthias ;
Block, Andreas ;
Heinemann, Volker ;
Illerhaus, Gerald ;
Moehler, Markus ;
Schenk, Michael ;
Kullmann, Frank ;
Behringer, Dirk M. ;
Heike, Michael ;
Pink, Daniel ;
Teschendorf, Christian ;
Loehr, Carmen ;
Bernhard, Helga ;
Schuch, Gunter ;
Rethwisch, Volker ;
von Weikersthal, Ludwig Fischer ;
Hartmann, Joerg T. ;
Kneba, Michael ;
Daum, Severin ;
Schulmann, Karsten ;
Weniger, Joerg ;
Belle, Sebastian ;
Gaiser, Timo ;
Oduncu, Fuat S. ;
Guentner, Martina ;
Hozaeel, Wael ;
Reichart, Alexander .
LANCET, 2019, 393 (10184) :1948-1957
[2]   Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial [J].
Alderson, Derek ;
Cunningham, David ;
Nankivell, Matthew ;
Blazeby, Jane M. ;
Griffin, S. Michael ;
Crellin, Adrian ;
Grabsch, Heike I. ;
Langer, Rupert ;
Pritchard, Susan ;
Okines, Alicia ;
Krysztopik, Richard ;
Coxon, Fareeda ;
Thompson, Joyce ;
Falk, Stephen ;
Robb, Clare ;
Stenning, Sally ;
Langley, Ruth E. .
LANCET ONCOLOGY, 2017, 18 (09) :1249-1260
[3]   Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer [J].
Allum, William H. ;
Stenning, Sally P. ;
Bancewicz, John ;
Clark, Peter I. ;
Langley, Ruth E. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) :5062-5067
[4]   Prognostic Significance of a New Grading System of Lymph Node Morphology After Neoadjuvant Radiochemotherapy for Esophageal [J].
Bollschweiler, Elfriede ;
Hoelscher, Arnulf H. ;
Metzger, Ralf ;
Besch, Sarah ;
Moenig, Stefan P. ;
Baldus, Stephan E. ;
Drebber, Uta .
ANNALS OF THORACIC SURGERY, 2011, 92 (06) :2020-2027
[5]   Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial [J].
Cunningham, David ;
Stenning, Sally P. ;
Smyth, Elizabeth C. ;
Okines, Alicia F. ;
Allum, William H. ;
Rowley, Sam ;
Stevenson, Laura ;
Grabsch, Heike I. ;
Alderson, Derek ;
Crosby, Thomas ;
Griffin, S. Michael ;
Mansoor, Wasat ;
Coxon, Fareeda Y. ;
Falk, Stephen J. ;
Darby, Suzanne ;
Sumpter, Kate A. ;
Blazeby, Jane M. ;
Langley, Ruth E. .
LANCET ONCOLOGY, 2017, 18 (03) :357-370
[6]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[7]   Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial [J].
Davarzani, Nasser ;
Hutchins, Gordon G. A. ;
West, Nicholas P. ;
Hewitt, Lindsay C. ;
Nankivell, Matthew ;
Cunningham, David ;
Allum, William H. ;
Smyth, Elizabeth ;
Valeri, Nicola ;
Langley, Ruth E. ;
Grabsch, Heike I. .
HISTOPATHOLOGY, 2018, 72 (07) :1180-1188
[8]   Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma [J].
Davies, A. R. ;
Myoteri, D. ;
Zylstra, J. ;
Baker, C. R. ;
Wulaningsih, W. ;
Van Hemelrijck, M. ;
Maisey, N. ;
Allum, W. H. ;
Smyth, E. ;
Gossage, J. A. ;
Lagergren, J. ;
Cunningham, D. ;
Green, M. .
BRITISH JOURNAL OF SURGERY, 2018, 105 (12) :1639-1649
[9]   Tumor-draining lymph nodes: At the crossroads of metastasis and immunity [J].
du Bois, Haley ;
Heim, Taylor A. ;
Lund, Amanda W. .
SCIENCE IMMUNOLOGY, 2021, 6 (63)
[10]   Impact of neoadjuvant chemotherapy on nodal regression and survival in oesophageal adenocarcinoma [J].
Evans, Richard P. T. ;
Kamarajah, Sivesh K. ;
Kunene, Victoria ;
Zardo, Davide ;
Elshafie, Mona ;
Griffiths, Ewen A. .
EJSO, 2022, 48 (05) :1001-1010